文献速递心脑血管急症复苏、休克与脓毒症

主动脉内球囊反搏降低急性心肌梗死合并早期心源性休克的30天死亡率:基于SCAI分型

INTRA-AORTIC BALLOON PUMP REDUCES 30-DAY MORTALITY IN EARLY-STAGE CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION ACCORDING TO SCAI CLASSIFICATION.
PubMed 文献 · Shock · 2023-08-04
一句话结论在急性心肌梗死合并早期心源性休克患者中,主动脉内球囊反搏与SCAI A/B期患者30天死亡率降低相关(1.2% vs 5.8%),C/D/E期无此关联。

该研究基于多中心临床试验(NCT04996901)回顾性分析5343例ST段抬高型心肌梗死患者,其中299例接受主动脉内球囊反搏。按SCAI SHOCK分期分层,SCAI分期与30天死亡率相关(OR 20.19)。倾向性评分匹配的580例患者中,IABP与不同休克分期间存在显著交互作用(P=0.005);A/B期患者接受IABP后30天死亡率显著降低(5.8% vs 1.2%,OR 0.19,P=0.034),C/D/E期无显著差异(29.3% vs 38.1%,OR 1.49,P=0.172)。结论提示IABP可能降低早期AMICS患者30天死亡率,SCAI分期有助于识别可能对IABP反应良好的患者。

要点

  • SCAI SHOCK分期与30天死亡率独立相关(OR 20.19,95%CI 13.60-29.97,P<0.001)。
  • 匹配队列中IABP与休克分期间交互作用显著(P=0.005)。
  • SCAI A/B期患者接受IABP后30天死亡率更低(5.8% vs 1.2%,OR 0.19,95%CI 0.03-0.73,P=0.034)。
  • SCAI C/D/E期患者接受IABP后30天死亡率无显著差异(29.3% vs 38.1%,OR 1.49,95%CI 0.84-2.65,P=0.172)。
  • 加权队列敏感性分析证实上述结果。

适用人群与场景

  • 基于多中心临床试验(NCT04996901)的ST段抬高型心肌梗死患者,共5343例,其中299例接受IABP。

诊断标准与关键阈值

  • 采用SCAI SHOCK分期对休克严重程度进行分级(A/B期与C/D/E期)。

研究设计与关键结果

  • 回顾性分析基于多中心临床试验(NCT04996901),纳入5343例ST段抬高型心肌梗死患者,299例接受IABP。
  • SCAI SHOCK分期与30天死亡率相关(OR 20.19,95%CI 13.60-29.97,P<0.001)。
  • 倾向性评分匹配后580例患者中,IABP与30天死亡率在不同休克分期间存在显著交互作用(P=0.005)。
  • SCAI A/B期患者中,IABP组30天死亡率5.8% vs 对照组1.2%(OR 0.19,95%CI 0.03-0.73,P=0.034)。
  • SCAI C/D/E期患者中,IABP组30天死亡率29.3% vs 对照组38.1%(OR 1.49,95%CI 0.84-2.65,P=0.172)。
  • 加权队列敏感性分析证实上述结果。

证据类型、等级与局限

  • 证据类型:基于多中心临床试验(NCT04996901)的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,IABP可降低早期AMICS患者30天死亡率,SCAI SHOCK分期有助于风险分层并识别可能对IABP反应良好的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Background: Cardiogenic shock complicating acute myocardial infarction (AMICS) remains a high 30-day mortality. Mechanical circulatory support devices are increasingly used in AMICS, but their effects on mortality vary partly because of shock severity. Aims: This study aimed to evaluate the association between intra-aortic balloon pump (IABP) and 30-day mortality in patients with early-stage AMICS. Methods: We retrospectively analyzed patients with ST-segment elevation myocardial infarction (STEMI) based on a multicenter clinical trial (NCT04996901). Patients were stratified by IABP use, and shock severity was classified according to the Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK stages. The primary outcome was 30-day all-cause mortality. The association between IABP and 30-day mortality was evaluated across shock stages using propensity score matching, weighting, and logistic regression. Results: Five thousand three hundred forty-three patients were included, and 299 received IABP. The SCAI SHOCK stage was associated with 30-day mortality (odds ratio [OR], 20.19; 95% confidence interval [CI], 13.60-29.97; P < 0.001). In the 580 matched patients, a significant interaction between IABP and 30-day mortality at different shock stages was observed ( P = 0.005). Intra-aortic balloon pump was associated with lower 30-day mortality among patients with shock stage A/B (5.8% vs. 1.2%; OR, 0.19; 95% CI, 0.03-0.73; P = 0.034) but not stage C/D/E (29.3% vs. 38.1%; OR, 1.49; 95% CI, 0.84-2.65; P = 0.172). These results were confirmed by sensitivity analyses of the weighted cohort. Conclusions: Intra-aortic balloon pump reduced 30-day mortality in patients with early-stage AMICS. The SCAI SHOCK stage provides risk stratification for patients with STEMI and helps identify those who may respond well to IABP.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Luo D, Huang R, Wang X, et al. INTRA-AORTIC BALLOON PUMP REDUCES 30-DAY MORTALITY IN EARLY-STAGE CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION ACCORDING TO SCAI CLASSIFICATION. Shock. 2023. PMID: 37548623. doi:10.1097/SHK.0000000000002184

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。